Sanofi
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Sanofi sits in the top decile of US sponsors by registered trial count (#47 of 15,742 sponsors by registered trial count).
Sanofi: 713 sponsored US clinical trials, 69 recruiting.
Sanofi sponsors 713 registered US clinical trials on ClinicalTrials.gov, 69 of them currently recruiting, and 490 completed. 364 of these trials are in Phase 3-4 (later-stage) and 316 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dermatitis, Atopic, with 9 trials.
Top-decile sponsor footprint
Sanofi ranks in the top decile of sponsors by registered trial count (#47 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
490 of 597 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
713 total, page 6 of 15
A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period
NCT03414736
Acne Vulgaris Related Microbiology and Serology
NCT04056598
Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
NCT03367819
A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide
NCT03387657
A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers
NCT06188325
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients
NCT03275285
A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
NCT03236311
Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
NCT03284957
Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)
NCT03260868
Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine
NCT03211858
Sotagliflozin Bioequivalence Study
NCT03211195
A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors
NCT03192345
A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)
NCT02803918
Evaluation of Dupilumab in Children With Uncontrolled Asthma
NCT02948959
Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia
NCT02999633
Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis
NCT02859896
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients
NCT02990338
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
NCT02921971
A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps
NCT02912468
A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus
NCT02973321
Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps
NCT02898454
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
NCT02878603
A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol
NCT02940379
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
NCT02890992
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
NCT02776735
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
NCT02787551
Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
NCT02738151
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
NCT02688933
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus
NCT02735044
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
NCT02642159
Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma
NCT02573233
A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients
NCT02625636
Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion
NCT02603510
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
NCT02585778
Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma
NCT02528214
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma
NCT02514668
A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
NCT02536937
28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension
NCT02531152
Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide
NCT02379390
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)
NCT02451137
SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients
NCT02283775
Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis
NCT02345070
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
NCT02414854
Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)
NCT02332590
A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.
NCT05976373
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
NCT02320721
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine
NCT02294474
A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants
NCT05976360
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
NCT02273180
A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth
NCT06193304
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 147 |
| Phase 2 | 169 |
| Phase 3 | 295 |
| Phase 4 | 69 |
What is open in the Sanofi pipeline
69 recruiting of 713 indexed (10% open); 490 completed (69%).
Phase mix: 364 late (III/IV) vs 316 early (I/II) (balanced across stages).
Top condition: Dermatitis, Atopic (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sanofi: open-pipeline peers nationwide
Peers matched on 713 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Sanofi sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 713 trials (± recruiting share)
- Icahn School of Medicine at Mount Sinai · 708 trials · 23% recruiting
- University of Miami · 721 trials · 20% recruiting
- Weill Medical College of Cornell University · 701 trials · 18% recruiting
- The University of Texas Health Science Center, Houston · 732 trials · 20% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Children's Hospitals and Clinics of Minnesota · 10% recruiting · 31 trials
- Cytokinetics · 10% recruiting · 31 trials
- Children's Oncology Group · 10% recruiting · 342 trials
- University of North Carolina, Chapel Hill · 10% recruiting · 1,109 trials
Related
What to do with this Sanofi page
713 registered trials is a research-attention snapshot, not an endorsement of Sanofi or any single study.
- 69 of Sanofi's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Dermatitis, Atopic is the condition Sanofi studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dermatitis, Atopic trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sanofi pipeline card: 713 registered trials from official public datasets.Report a data error.